Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Sold by First Hawaiian Bank

First Hawaiian Bank decreased its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 2.8% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,973 shares of the biopharmaceutical company’s stock after selling 175 shares during the period. First Hawaiian Bank’s holdings in Intra-Cellular Therapies were worth $413,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in ITCI. Kapitalo Investimentos Ltda acquired a new position in Intra-Cellular Therapies during the 4th quarter worth approximately $26,000. HighPoint Advisor Group LLC acquired a new position in Intra-Cellular Therapies during the fourth quarter worth $217,000. Vanguard Group Inc. raised its position in Intra-Cellular Therapies by 6.5% in the fourth quarter. Vanguard Group Inc. now owns 9,094,302 shares of the biopharmaceutical company’s stock worth $651,334,000 after acquiring an additional 554,577 shares in the last quarter. Goldman Sachs Group Inc. raised its position in Intra-Cellular Therapies by 52.6% in the fourth quarter. Goldman Sachs Group Inc. now owns 578,615 shares of the biopharmaceutical company’s stock worth $41,440,000 after acquiring an additional 199,503 shares in the last quarter. Finally, Virtu Financial LLC purchased a new stake in shares of Intra-Cellular Therapies during the 4th quarter worth $546,000. 92.33% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on ITCI. The Goldman Sachs Group increased their price target on shares of Intra-Cellular Therapies from $67.00 to $77.00 and gave the company a “neutral” rating in a report on Wednesday, April 17th. JPMorgan Chase & Co. lifted their price target on shares of Intra-Cellular Therapies from $75.00 to $78.00 and gave the company an “overweight” rating in a research report on Wednesday, June 12th. Canaccord Genuity Group upped their price target on Intra-Cellular Therapies from $107.00 to $113.00 and gave the stock a “buy” rating in a report on Thursday. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $120.00 price objective on shares of Intra-Cellular Therapies in a report on Friday, June 14th. Finally, Bank of America upped their target price on Intra-Cellular Therapies from $82.00 to $91.00 and gave the company a “buy” rating in a report on Wednesday, April 17th. Two equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $92.67.

Intra-Cellular Therapies Stock Up 1.4 %

ITCI opened at $76.58 on Friday. The business’s fifty day simple moving average is $69.53 and its 200 day simple moving average is $68.69. Intra-Cellular Therapies, Inc. has a 52 week low of $45.50 and a 52 week high of $84.89.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.15. The company had revenue of $144.90 million for the quarter, compared to analyst estimates of $141.41 million. Intra-Cellular Therapies had a negative net margin of 21.57% and a negative return on equity of 18.49%. The firm’s quarterly revenue was up 52.0% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.46) EPS. On average, equities analysts expect that Intra-Cellular Therapies, Inc. will post -0.51 EPS for the current fiscal year.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.